Personalis narrows 2025 revenue outlook to $68M-$73M amid biopharma project delays and rapid clinical test growth (NASDAQ:PSNL)

Group 1 - The article does not provide any specific content related to a company or industry, as it appears to be a technical issue regarding browser settings and ad-blockers [1]